BioArctic and Eisai report FDA extension of Leqembi Iqlik review

Mezzion reveals pre-IND FDA feedback on udenafil development in ADPKD

Altasciences and Certara form strategic partnership to accelerate early drug development

Partner Therapeutics' BIZENGRI receives FDA Commissioner's National Priority Voucher for NRG1 fusion-positive cholangiocarcinoma

Diakonos Oncology's DOC1021 granted US FDA Fast Track Designation for unresectable or metastatic cutaneous melanoma

ZYUS Life Sciences receives second US pain management patent

Citius Oncology to accelerate LYMPHIR commercialisation with up to USD36.5m in debt and equity capital

Alebund Pharmaceuticals completes AP301 Phase III clinical trial patient enrolment for hyperphosphataemia

Neurocrine Biosciences survey shows significant burden of tardive dyskinesia on employment and education

Atossa Therapeutics' (Z)-endoxifen receives FDA Rare Pediatric Disease designation for McCune-Albright Syndrome

Xbrane resubmits FDA application for ranibizumab biosimilar after facility remediation

Sprout Pharmaceuticals named one of TIME's most influential health and life sciences companies of 2026

European Commission clears first pertuzumab biosimilar in Europe

Vanda Pharmaceuticals reports publication of imsidolimab phase III findings in NEJM Evidence

C-Ray Therapeutics' Copper-64 (Cu-64) Type II DMF gains FDA acceptance